Form 4: Voyager Therapeutics COO Robin Swartz Reports Sale of Common Stock for Tax Obligations
SEC Form 4 Filing
Robin Swartz, Chief Operating Officer of Voyager Therapeutics, sold 1,357 shares of common stock on April 2, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- On April 2, 2024, Robin Swartz, the Chief Operating Officer of Voyager Therapeutics, sold 1,357 shares of the company's common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on April 1, 2024.
- The shares were sold at a weighted average price of $9.88, with individual transactions ranging from $9.83 to $10.01.
- Following the reported transaction, Swartz beneficially owns 117,004 shares of Voyager Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock sales for tax purposes. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading activity by company insiders. This filing indicates that the COO sold shares to cover tax obligations, which is a common practice.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Restricted stock units vested, triggering tax withholding obligations. |
| 04/02/2024 | Robin Swartz sold 1,357 shares of Voyager Therapeutics common stock. |
| 04/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.